EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Small Molecule Inhibitors Targeting the “Undruggable” Survivin: The Past, Present, and Future from a Medicinal Chemist’s Perspective

Qingbin Cui iD, Caoqinglong Huang, Jing-Yuan Liu, Jian-Ting Zhang iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c01130 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Qingbin Cui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Cancer Biology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio 43614, United States. Hauptthemen laut MEDLINE: Inhibitor of Apoptosis Proteins, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 217 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Survivin, a homodimeric protein and a member of the IAP family, plays a vital function in cell survival and cycle progression by interacting with various proteins and complexes. Its expression is upregulated in cancers but not detectable in normal tissues. Thus, it has been regarded and validated as an ideal cancer target. However, survivin is "undruggable" due to its lack of enzymatic activities or active sites for small molecules to bind/inhibit. Academic and industrial laboratories have explored different strategies to overcome this hurdle over the past two decades, with some compounds advanced into clinical testing. These strategies include inhibiting survivin expression, its interaction with binding partners and homodimerization. Here, we provide comprehensive analyses of these strategies and perspective on different small molecule survivin inhibitors to help drug discovery targeting "undruggable" proteins in general and survivin specifically with a true survivin inhibitor that will prevail in the foreseeable future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inhibitor of Apoptosis ProteinsNeoplasmsHumansSurvivinDrug DiscoveryDimerizationApoptosis

Substanzen

SurvivinInhibitor of Apoptosis Proteins

Autor:innen und Institutionen

  • Department of Cell and Cancer Biology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio 43614, United States.
  • Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio 43614, United States.

ORCID-Profile: Qingbin Cui, Jian-Ting Zhang

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Cui, Q., Huang, C., Liu, J. Y., & Zhang, J. T. (2023). Small Molecule Inhibitors Targeting the “Undruggable” Survivin: The Past, Present, and Future from a Medicinal Chemist’s Perspective. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01130

Vancouver

Cui Q, Huang C, Liu JY, Zhang JT. Small Molecule Inhibitors Targeting the “Undruggable” Survivin: The Past, Present, and Future from a Medicinal Chemist’s Perspective. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01130

BibTeX
@article{Cui2023,
  author = {Cui, Qingbin and Huang, Caoqinglong and Liu, Jing-Yuan and Zhang, Jian-Ting},
  title = {Small Molecule Inhibitors Targeting the “Undruggable” Survivin: The Past, Present, and Future from a Medicinal Chemist’s Perspective},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c01130}
}
Kostenlos starten →